New Sickle Cell Anemia Therapy Advances to Phase II Clinical Trials
La Jolla Institute for ImmunologySeeking to improve the lives of sickle cell anemia sufferers around the world, researchers from the La Jolla Institute for Allergy and Immunology, the Dana-Farber/Children's Hospital Cancer Center in Boston and the BloodCenter of Wisconsin in Milwaukee and others are preparing to launch Phase II of a clinical trial to investigate a potential new therapy for reducing the disorder’s severest symptoms. More than 100,000 Americans and several million people worldwide suffer from this genetic disorder.